INTRODUCTION: Nodular regenerative hyperplasia (NRH) has been associated with thiopurine therapy in patients with inflammatory bowel disease (IBD), but prevalence and prognosis of NRH remain unclear. This study is a cross-sectional search for NRH in IBD patients with long-term azathioprine or 6-mercaptopurine treatment.
MATERIAL AND METHODS: Thirty-three IBD patients with continuous azathioprine/6-mercaptopurine treatment for at least 5 years were included. Laboratory tests, thiopurine metabolite levels, liver histology, MRI were examined for NRH and signs of portal hypertension.
RESULTS: NRH was not observed in this cohort of 33 patients. Nevertheless, some possibly related signs of vascular changes were found by MRI in three patients. Also, splenomegaly, which may be associated with portal hypertension, was found in one patient. No high thiopurine dose neither high metabolite levels were found in these patients.
CONCLUSION: No NRH was found in this group of IBD patients with long-term azathioprine/6-mercaptopurine treatment. Larger multicenter studies are needed to determine the prevalence of NRH in thiopurine-treated IBD patients.
|Number of pages||6|
|Journal||European Journal of Gastroenterology & Hepatology|
|Issue number||1S Suppl 1|
|Publication status||Published - 1 Dec 2021|
- inflammatory bowel disease
- nodular regenerative hyperplasia
- LOW-DOSE 6-THIOGUANINE
- IBD PATIENTS
- 6-MERCAPTOPURINE THERAPY